CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenue
Operating expenses:
General and administrative (including stock-based compensation (Note 7))	2,348,324	2,078,248
Depreciation	1,161	827
Research and development (including stock-based compensation (Note 7))	200,691	748,545
Total operating expenses	2,550,176	2,827,620
Loss from operations	(2,550,176)	(2,827,620)
Other (income) expense:
Forgiveness of debt		(34,800)
Interest income	(5,625)
Interest expense	301,659	657,945
Gain on sale of domain (Note 9)	(902,490)
Gain on legal dissolution of subsidiary (Note 5)	(10,234,501)
Total other expense	(10,840,957)	623,145
Net income (loss)	8,290,781	(3,450,765)
Net loss attributable to the noncontrolling interest	1,544	2,785
Net income (loss) applicable to Bion's common stockholders	$ 8,292,325	$ (3,447,980)
per basic and diluted common share	$ 0.20	$ (0.10)
Weighted-average number of common shares outstanding:
Basic and diluted	41,962,302	33,068,832